Mar. 17 at 11:56 AM
$CMMB Wouldn't surprise me if they license Nebokitug for SSC instead of PSC for P3 and use the funds to pay for P3 trial solo. Big pharma sees SSC as a larger addressable market and have the manpower to recruit and see P2/P3 trials through for SSC. Deal structure would give CMMB some upfront cash (
$100M-
$150M)--funding P3 for PSC outright, along with milestone payments upon successful P2 and P3 enrollment/readouts (200-700M) along with royalties (10-15%) post approval. This would be very shareholder friendly with dilution risk removed and upside capture on SSc. This would also allow management to focus solo on PSC P3 completion. They could also start R/D on some of the other larger addressable ailments (liver fibrosis, NASH/MASH, cardiac fibrosis, ILF, autoimmune) that could potentially benefit from a ccl-24 neutralizing antibody. See how this plays out as I believe they have many avenues to address the financial/dilution risk that has been plaquing the share price
